English Polski
Vol 12, No 1 (2019)
Research paper
Published online: 2019-06-12

open access

Page views 973
Article views/downloads 2030
Get Citation

Connect on Social Media

Connect on Social Media

Availability of the platelet concentrates for immunized patients from donors with HLA and HPA typed antigens

Katarzyna Guz1, Patrycja Łopacz1, Agnieszka Gierszon1, Agnieszka Orzińska1, Małgorzata Uhrynowska1, Krystyna Maślanka1, Ewa Brojer1
Journal of Transfusion Medicine 2019;12(1):1-12.

Abstract

Clinical efficacy of PC transfusions in patients immunized with Human Leukocyte Antigens (HLA) and/or Human Platelet Antigens (HPA) can be improved by relying on platelets from donors typed for HPA and/or HLA. A specific group of PC recipients are newborns with alloimmune thrombocytopenia (FNAIT) resulting from maternal alloimmunization during pregnancy against specific fetal platelet antigens HPA (especially HPA-1a) produced by the mother as a result of fetomaternal HPA incompatibility. The study aim was to assess the demand and availability for HPA/HLA typed donors in Poland. Outcome of a survey distributed to 23 Polish blood transfusion centers (CKiK) supplemented by data acquired in direct contact (phone) revealed that: 1/ demand for PCs from donors with HLA and/or HPA typed antigens was reported in 7/23 (33.3%) CKiK; 2 / over a 1.5 year period, 1 788 PCs were prepared for patients with anti-HLA- antibodies, 63 PCs for patients with anti-HPA-antibodies and 58 PCs - for patients with anti-HLA and anti-HPA antibodies. FNAIT neonates were transfused with 35 PCs from register donors and 176 PCs from casual donors; 3 / in 13/23 CKiK (61.9%) PC selection for immunized patients was mainly based on crossmatching in LCT; 4 / registers report of 12,885 donors typed for HLA Class I antigens including 417 donors typed for HPA; 5 / nation-wide there are 133 HPA-1a negative donors available for immunized patients; they were selected after typing of 5 872 donors; The number of HPA/HLA typed donors for immunized patients is insufficient. as compared to other countries. Moreover, the demand for registered donors is steadily growing due to expension of FNAIT diagnostics currently performed at the Institute of Hematology and Transfusion Medicine (IHiT) but also in the laboratories of CKiK. One of the responsibilities of the blood transfusion service is to provide PCs for immunized patients.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015; 162(3): 205–213.
  2. Klein HG, Anstee DJ. Immunology of leucocytes, plateletes and plasma components. W: Mollison’s blood transfusion in clinical medicine. 12th Edition. Jphn Woley & Sons Ltd Oxford UK 2014; 549-610.
  3. Kumar A, Mhaskar R, Grossman BJ, et al. AABB Platelet Transfusion Guidelines Panel. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2015; 55(5): 1116–27; quiz 1115.
  4. Maślanka K, Łopacz P, Łętowska M. Zasady przetaczania koncentratów krwinek płytkowych. Robak T, Warzocha K, (red). Hematologia. Via Medica. Gdańsk 2016; 281-292.
  5. Kakaiya RM, Triulzi DJ, Wright DJ, et al. National Heart, Lung, and Blood Institute (NHLBI) Retrovirus Epidemiology Donor Study-II. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010; 50(6): 1328–1334.
  6. Maślanka K. Współczesne poglądy na występowanie oporności na przetaczanie koncentratów krwinek płytkowych. Acta Haematol Pol. 2011; 42: 453–485.
  7. Maślanka K, Uhrynowska M, Apel D, et al. Przydatność prób zgodności z użyciem limfocytów/płytek krwi w przewidywaniu skuteczności przetoczeń koncentratów krwinek płytkowych u chorych zimmunizowanych. Acta Haematol Pol. 2004; 35: 71–78.
  8. Forest SK, Hod EA. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am. 2016; 30(3): 665–677.
  9. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987; 70(6): 1722–1726.
  10. Maślanka K, Guz K, Uhrynowska M, et al. Rejestr dawców z oznaczonymi swoistymi antygenami płytek krwi (HPA) i jego zastosowanie w transfuzjologii. Acta Haematol Pol. 2005; 36: 189–196.
  11. Uhrynowska M, Niznikowska-Marks M, Zupańska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol. 2000; 64(1): 42–46.
  12. Kamphuis MM, Tiller H, van den Akker ES, et al. Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort. Fetal Diagn Ther. 2017; 41(4): 251–257.
  13. Uhrynowska ME, Dębska M, Guz K, et al. [PREVFNAIT prevention of foetal/neonatal alloimmune thrombocytopenia (FNAIT) in Polish foetuses and newborns--the PREVFNAIT program]. Ginekol Pol. 2015; 86(1): 62–66.
  14. Brojer E, Husebekk A, Dębska M, et al. Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention. Arch Immunol Ther Exp (Warsz). 2016; 64(4): 279–290.
  15. Guz K, Uhrynowska M, Kopeć I, et al. Recent advances in understanding the clinical relevance of antiplatelet alloantibodies. Pol Arch Intern Med. 2017; 127(3): 190–194.
  16. Dębska M, Uhrynowska M, Guz K, et al. Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a. Arch Med Sci. 2018; 14(5): 1041–1047.
  17. Żupańska B, Maślanka K, Michur H, et al. Jaką strategię należy zastosować, aby zwiększyć rozpo¬znawanie alloimmunologicznej małopłytkowości płodów i noworodków? Ginekologia po dyplomie. 2008; 4: 62–64.
  18. Allen D, Verjee S, Rees S, et al. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood. 2007; 109(1): 388–389.
  19. Kiefel V. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood. 2006; 107(9): 3761–3763.
  20. Lucas GF, Bendukidize N. HPA-1a(-), 5b(-) platelets for use in neonatal alloimmune thrombocytopenia--from 'Cinderella' product to standard component. Transfus Med. 2014; 24(2): 127–129.
  21. Allen DL, Samol J, Benjamin S, et al. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med. 2004; 14(6): 409–417.
  22. Kamphuis MM, Paridaans NP, Porcelijn L, et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014; 133(4): 715–721.
  23. Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang. 2003; 85(4): 326–327.
  24. Wróbel A, Guz K, Orzińska A, et al. Automatyzacja przesiewowego fenotypowania antygenu HPA-1a u kobiet ciężarnych – doświadczenia własne. Acta Haematologica Polonica. 2015; 46: 20–21.
  25. Skogen B, Bellissimo DB, Hessner MJ, et al. Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion. 1994; 34(11): 955–960.
  26. Ficko T, Galvani V, Rupreht R, et al. Real-time PCR genotyping of human platelet alloantigens HPA-1, HPA-2, HPA-3 and HPA-5 is superior to the standard PCR-SSP method. Transfus Med. 2004; 14(6): 425–432.
  27. Guz K, Krzemienowska M, Orzińska A, et al. Polimorfizm +24G>del w 3 intronie genu ITGB3 w regionie diagnostycznym genotypowania allelu HPA-1a: konsekwencje i metody weryfikacji. J Transfus Med. 2013; 6(2): 33–40.
  28. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79(4): 237–245.
  29. Merieux Y, Schwab C, Saint-Cyr M, et al. Evaluation of Diagnostic Tests by Evanescence Biosensor Technology for Rapid Phenotyping of the Human Platelet Alloantigens 1a and 5b. Transfusion Medicine and Hemotherapy. 2018.